13.15
-2.07 (-13.60%)
| Previous Close | 15.22 |
| Open | 14.42 |
| Volume | 1,162,481 |
| Avg. Volume (3M) | 635,057 |
| Market Cap | 569,846,016 |
| Price / Sales | 12.00 |
| 52 Weeks Range |
| Profit Margin | -104.64% |
| Operating Margin (TTM) | -65.71% |
| Diluted EPS (TTM) | -1.30 |
| Quarterly Revenue Growth (YOY) | 440.10% |
| Total Debt/Equity (MRQ) | 22.21% |
| Current Ratio (MRQ) | 4.62 |
| Operating Cash Flow (TTM) | -40.34 M |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Beta Bionics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.63 |
|
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product include the iLet Bionic Pancreas (iLet). The Company operates as single segment, focused on the development, manufacture and sale of the iLet. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| % Held by Insiders | 7.52% |
| % Held by Institutions | 57.74% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 31.00 (Ladenburg Thalmann, 135.74%) | Buy |
| Median | 27.00 (105.32%) | |
| Low | 20.00 (Baird, 52.09%) | Hold |
| Average | 26.67 (102.81%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 20.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Lake Street | 24 Feb 2025 | 30.00 (128.14%) | Buy | 20.60 |
| Leerink Partners | 24 Feb 2025 | 28.00 (112.93%) | Buy | 20.60 |
| Piper Sandler | 24 Feb 2025 | 26.00 (97.72%) | Buy | 20.60 |
| Stifel | 24 Feb 2025 | 25.00 (90.11%) | Buy | 20.60 |
| Baird | 20 Feb 2025 | 20.00 (52.09%) | Hold | 20.87 |
| Ladenburg Thalmann | 20 Feb 2025 | 31.00 (135.74%) | Buy | 20.87 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 May 2025 | Announcement | Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025 |
| 01 May 2025 | Announcement | Beta Bionics to Present at the Bank of America Securities Health Care Conference |
| 16 Apr 2025 | Announcement | Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025 |
| 09 Apr 2025 | Announcement | Beta Bionics to Host Investor Event on June 22, 2025 |
| 27 Mar 2025 | Announcement | Beta Bionics Announces Board Appointment of Gerard Michel |
| 25 Mar 2025 | Announcement | Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025 |
| 27 Feb 2025 | Announcement | Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |